Interactions Of The Human Immunodeficiency Virus And Tuberculosis And The Implications For Bcg Vaccination

Research output: Contribution to journalArticle

Abstract

AIDS has become a global epidemic, with >100,000 cases officially reported in 140 countries and an estimated 5-10 million asymptomatic carriers of the human immunodeficiency virus (HIV), the etiologic agent of AIDS. With an increase in HIV infection in some developing countries, there has been a resurgence in tuberculosis, and concern has been raised about the indications, efficacy, and safety of bacille Calmette-Guerin (BCG) vaccination. Anecdotal reports of local reactions and disseminated disease have been described in HIV-infected children and adults. Ten HIV-infected infants, who received BCG vaccination within 2 months of birth, developed local lymphadenitis at 4-15 months. However, in one preliminary survey in Zaire, the rates of local lymphadenitis were equal in HIV-infected and HIV-uninfected children, and no dissemination has been observed to date. Until further information is known, BCG vaccinations should not be given to symptomatic HIV-infected individuals and should only be given to HIV-infected children who are asymptomatic and who reside in areas where tuberculosis is highly endemic and where the risk of tuberculosis may outweigh the potential complications of BCG immunization.

Original languageEnglish (US)
Pages (from-to)S379-S384
JournalReviews of infectious diseases
Volume11
DOIs
StatePublished - Mar 1989

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this